Full year 2025 total revenue was $40.5 million, representing a 7% increase year-over-year and aligning with guidance. Fourth quarter 2025 total revenue reached $10.0 million, an 8% increase over the same quarter in the prior year. The company provides 2026 revenue guidance of $42 million to $44 million. Adjusted EBITDA for the full year 2025 improved to negative $6.7 million, compared to negative $14.5 million in 2024. Free Cash Flow for the full year 2025 was negative $9.8 million, a significant improvement from negative $13.5 million in 2024 and better than the previously communicated target of less than negative $12 million. Teknova aims to become Adjusted EBITDA positive by the end of 2027. Anticipates full-year Free Cash Outflow of less than $10 million in 2026. Cash and short-term investments totaled $21.3 million, and gross debt was $13.2 million at the end of fiscal year 2025. Achieved 25% annual growth in the number of Clinical Solutions customers in 2025.